Epistemis

Local and Systemic Oncological Therapies: Imiquimod, Topical 5-Fluorouracil and Vismodegib

  • Oncological Dermatology and Premalignant Lesions

Common trade names: Aldara (Imiquimod Cream 5%); Efudix (5-Fluorouracil Cream 5%); Erivedge (Vismodegib Capsules 150 mg).

Mechanism

Pharmacological Class and Group

Topical local immune response modulators (Imiquimod), topical antimetabolites (5-Fluorouracil) and systemic Hedgehog signaling pathway inhibitors (Vismodegib).

Mechanism of Action

Each compound destroys tumor cells through well-differentiated biological pathways:

  • Imiquimod: Acts as a potent and selective agonist of the pattern recognition receptors of the innate immune system: Toll-like receptors 7 (TLR7) on antigen-presenting cells (dendritic cells and macrophages of the epidermis). Its stimulation activates the MyD88-dependent signaling cascade, recruiting the transcription factor NF-κB. This stimulates a massive local transcription of proinflammatory antitumor cytokines such as Interferon-alpha (IFN-α), Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-12 (IL-12), activating an immune response mediated by CD8+ cytotoxic T lymphocytes that selectively destroys dysplastic epidermal cells.
  • Topical 5-Fluorouracil (5-FU): It is a synthetic analogue of pyrimidine that undergoes intracellular phosphorylation to form the active metabolite fluorodeoxyuridylate (FdUMP). This binds covalently and irreversibly to the key enzyme Thymidylate Synthase (TS), blocking the de novo synthesis of thymidine essential for cell duplication and stopping DNA replication and RNA transcription in actinic keratosis hyperproliferative dysplastic tumor cells.
  • Vismodegib: Small oral molecule that acts as a specific, high-affinity antagonist of the SMO (Smoothened) transmembrane receptor in the Hedgehog signaling pathway (constitutively mutated and hyperactive in more than 90% of basal cell carcinomas). By blocking SMO, the cytoplasmic release and translocation of GLI family transcription factors (GLI1 and GLI2) is stopped, turning off the expression of genes for proliferation, angiogenesis and tumor invasion of basal cell carcinoma.

Inhibition Mechanism of the Hedgehog Pathway in CBC

In BCC, loss of function of the tumor suppressor protein PTCH1 or mutational activation of SMO causes constitutive activation of the pathway. Vismodegib works by directly blocking this aberrant tumor replication cascade:

Vismodegib SMO Blockade GLI1/2 Arrest Cellular Regression of Basal Cell Carcinoma

This promotes rapid cell cycle arrest and apoptosis of tumor cells from locally advanced nodular, ulcerated or infiltrative basal cell carcinoma.

Pharmacokinetics

High Resolution Pharmacokinetics

  • Systemic Absorption: Imiquimod and 5-FU applied topically to intact skin have negligible systemic absorption (<0.9% for imiquimod; <2-6% for 5-FU), which limits their systemic hematological toxicity. However, its application on large eroded surfaces can increase absorption. Oral Vismodegib has a high bioavailability of 85%, reaching stable maximum serum concentrations in 2-4 weeks of use.
  • Metabolism: Vismodegib is metabolized in the liver by oxidation mediated mixed by CYP2C9 and CYP3A4.
  • Excretion: Vismodegib is mainly eliminated unchanged in feces and bile (82%); renal excretion is less than 4%.
  • Half-life (t1/2): Vismodegib has an extremely long terminal elimination half-life of 12 days (tissue retention of more than a month after discontinuation of therapy).

Indicators and dose

Clinical Indications and Off-Label Uses

Indications of Imiquimod / 5-FU
  • Multiple and confluent actinic keratosis on the face, neck and scalp (field therapy).
  • Small superficial basal cell carcinoma (<2 cm) located in the trunk or extremities where surgery is contraindicated.
  • Condylomata acuminata (external genital and perianal warts, with imiquimod).
Indications of Vismodegib
  • Locally Advanced Basal Cell Carcinoma (BCCla) that is not a candidate for curative surgical resection or radiotherapy.
  • Metastatic Basal Cell Carcinoma (mBCC).
  • Basal cell nevus syndrome (Gorlin-Goltz syndrome, off-label) for suppression and chemoprevention of multiple primary carcinomas.

Dosage and Clinical Adjustment

Imiquimod Cream 5% (Actinic Keratoses):

  • Apply to the affected area in a thin layer 3 times a week (e.g., Monday, Wednesday and Friday) before going to bed, leaving the product to act for a period of 8 hours. Remove in the morning with mild soap and water. Continue for a full 16 week cycle.
  • Superficial Basal Cell Carcinoma: Apply 5 times per week (Monday to Friday) for a complete cycle of 6 weeks.

5-Fluorouracil Cream 5% (Actinic Keratoses):

  • Apply a very thin layer to the lesions twice a day after gentle cleansing. Avoid rubbing vigorously. Maintain the cycle for 2 to 4 continuous weeks, until reaching the characteristic maximum erosive inflammatory phase.

Vismodegib (Advanced Basal Cell Carcinoma):

  • 150 mg orally once a day continuously, until resolution of the tumor or appearance of intolerable limiting toxicity.

Adjustment in Renal/Hepatic Failure: There are no established adjustment guidelines for vismodegib in mild-moderate renal failure or hepatic dysfunction; monitor for the appearance of painful muscle spasms.

Security

Absolute and Relative Contraindications

Contraindications of Imiquimod / 5-FU
  • Known hypersensitivity to the active ingredients.
  • Dihydropyrimidine Dehydrogenase (DPD) enzyme deficiency (for 5-FU): A genetic deficiency of DPD prevents the clearance of the fraction of absorbed systemic 5-FU, inducing fatal profound neutropenia, colitis and neurotoxicity.
Contraindications of Vismodegib
  • Pregnancy or imminent risk of it: Major absolute and abortive teratogen (induces embryonic cyclopia due to interference with midline development).
  • Concomitant use of strong CYP3A4 inducers.

Adverse Effects (ADR) and Specific Toxicity

  • Very common (>50% with topical Imiquimod / 5-FU): Intense local inflammatory reactions expected (severe erythema, formation of meliceric crusts, dermoepidermal erosions, burning and ulceration, indicative of successful immune elimination of tumor cells).
  • Very common (>30% with Vismodegib): Generalized painful muscle spasms, severe diffuse alopecia, dysgeusia or complete ageusia (loss of taste due to inhibition of the turnover of the sensory receptor of taste buds), involuntary weight loss, extreme asthenia and nausea.
  • Rare (<0.1%): Transient systemic flu-like symptoms (associated with systemic absorption of imiquimod and release of interferon), severe pancytopenia (due to 5-FU in DPD deficiency).

Critical Toxicity: Vismodegib Teratogenic Alert and the Prevention Program

The Hedgehog signaling pathway is the main morphogenetic driver responsible for the bilateral symmetry segmentation of the embryo and the development of the midline and limbs during the first weeks of gestational life. Exposure to vismodegib invariably causes embryonic death or induces brutal skeletal and craniofacial anomalies incompatible with life (such as cyclopia or severe medial holoprosencephaly):

Vismodegib Sonic Hedgehog Signaling Failure Cyclopia and Fetal Holoprosencephaly

It is mandatory that women of childbearing potential use two effective contraceptive methods simultaneously during treatment and maintain it for a minimum of 24 months after taking the last dose of vismodegib. Due to the presence of the active drug in the sperm, treated men must use condoms in their sexual relations with women of childbearing age during treatment and up to 3 months after stopping the drug.

Drug Interactions of Clinical Relevance

  • CYP3A4 inducers (Rifampin, Carbamazepine): They significantly reduce the stable plasma concentration of vismodegib, with the risk of tumor therapeutic failure.
  • No systemic interactions relevant to the appropriate topical use of imiquimod or 5-fluorouracil are described.

Safety in Pregnancy and Breastfeeding

  • Pregnancy: FDA Category All topical and systemic oncological active ingredients described are absolutely contraindicated.
  • Breastfeeding: Absolutely contraindicated. Excretion in milk is unknown, but the high potential for cellular toxicity in the infant requires its total restriction.

Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.

PreviousAntiparasitics: Ivermectin (Topical and Systemic) and Permethrin
System
Dermatology
Cluster
Oncological Dermatology and Premalignant Lesions
Download Epistemis